Search Results

Development of cellular therapy for CMML and the Immune landscape of response and resistance

We will test the efficacy of CAR T cell therapy for CMML. We will modify the tumor microenvironment to enhance their efficacy. and we will upscale CAR…

Huda Salman

My clinical and research interest is to develop therapies that enhance the immune system to fight blood cancer. I serve as the IND holder responsible …

Sam Butterworth

Sam Butterworth joined the University of Manchester as a Senior Lecturer in Medicinal Chemistry in November . Prior to this he worked at the Universit…

Development of peptide-drug conjugates for the treatment of Chronic Myelomonocytic Leukaemia (CMML)

We are aiming to bring a new treatment option to patients with chronic myelomonocytic leukemia (CMML) by utilising CCL2-drug conjugates that specifica…

CLL-1 CAR-T cells and trametinib for the treatment of Ras-mutated CMML and JMML

hypothesize that demonstrating activity of (CLL1CART) cell therapy with or without trametinib in models of chronic myelomonocytic leukemia (CMML) a…

Elliot Stieglitz

Dr. Elliot Stieglitz is a at the University of California, San Francisco whose research focuses on children diagnosed with juvenile myelomonocytic le…

Eric Padron

Eric Padron, MD is an Associate Member and Scientific Director of the Department of Hematology at Moffitt Cancer Center (MCC). He completed a hematolo…

Advancing the therapeutic landscape for Chronic Myelomonocytic Leukemia (CMML)

CMML is a universally lethal blood cancer characterized by increased monocytes (a type of white blood cell) in the peripheral blood and abnormal appea…

A phase 1 study of VIPER-101, a CD5-edited dual population chimeric antigen receptor cell therapy, to enhance immunotherapy against T-cell non-Hodgkin lymphoma

In October , LLS made an equity investment in Vittoria to "Support Clinical Development of , a Cell Therapy for lymphomas."Vittoria Biotherapeutics …

Resources for blood cancer patients

Therapy Acceleration Program® (TAP)

Beat AML®

Targeting Leukemia Stem Cells with the Novel Antibody Drug Conjugate

To improve the cure rate of patients suffering from acute myeloid leukemia (AML), our study aims to target resistant leukemia stem cells by developing…

George Daley

George Q. Daley, MD, PhD is Dean, Caroline Shields Walker Professor of Medicine, and Professor of Biological Chemistry and Molecular Pharmacology at H…

Sheng Li

Dr. Sheng Li is an Associate Professor in the Department of Biochemistry and Molecular Medicine, with a secondary appointment in the Department of Tra…

Ivan Odak

My name is Ivan Odak and I am a postdoctoral researcher in the Brody lab. I am an accomplished researcher with authored papers, of which as first or…

Marina Konopleva

Dr. Konopleva is a Director of the Acute Leukemia Program and a of the Translational Blood Cancer Institute at Einstein/Montefiore Cancer Center, NY.…

Pooja Khandelwal

I am a pediatric oncologist and associate professor in the division of bone marrow transplantation at Cincinnati Children’s Hospital Medical Center. I…

Anouchka Laurent

My research interests are the identification of genetic alterations responsible for leukemia and lymphoma development and the elucidation of the mecha…

Anita Kumar

Anita Kumar, MD is an Associate Attending at Memorial Sloan Kettering Cancer Center where she specializes in mantle cell lymphoma. Dr. Kumar leads the…

Jeetayu Biswas

I am an MD/PhD physician scientist in the oncology fellowship at MSKCC where I treat leukemia and perform research to understand molecular underpinnin…

Sham Mailankody

I am a medical oncologist with the Myeloma Service and a member of the Cellular Therapeutics Center and the Center for Health Policy and Outcomes at M…

Michaela Reagan

Dr. Michaela Reagan is a Faculty Scientist II at the MaineHealth Institute for Research and an Associate Professor at Tufts University School of Medic…

Eli

Sobreviviente de LinfomaIndianapolis, IN de marzo de . Nunca voy a olvidar el momento en que vi por primera vez el bulto. Acudimos al pediatra esa ta…

Mark

Sobreviviente de LinfomaHays, KS A la edad de años, mi padre, Mark Brightbill, recibió un diagnóstico de linfoma de Hodgkin en etapa y se sometió a …